Eurocine Vaccines AB announced that the company has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2, HSV-2, based on the technologies developed by Redbiotec. The agreement covers both an mRNA and a protein-based technology, its documentation and patents within the field of HSV-2. By entering this agreement, all activities related to the development, manufacture and commercialization until an out-licensing agreement with a third party is signed, will be managed and financed by Eurocine Vaccines.

The proceeds from any future out-licensing or granting of rights to third parties shall be shared between Eurocine Vaccines and Redbiotec, dependent on the project´s development stage at which the agreement with the third party is entered. Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise. Immediate action points following the signing of this agreement include; Planning the forthcoming development, including preclinical and clinical studies, documentation, patents and business development along with active marketing.

Deciding which technology to pursue – the mRNA or protein-based vaccine candidate. Evaluate the potential of a prophylactic HSV-2 vaccine to follow the development of this therapeutic vaccine, and the potential synergies of these two.